Search Results 191-200 of 17298 for egfr

  1. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    ... (EGFR), defined as follows: EGFR mutation testing of tumor has been performed and did not demonstrate an EGFR tyrosine kinase inhibitor sensitizing mutation ...

  2. A Study to Understand Serum Biotin Clearance as a Means to Mitigate the Risk of Biotin Interference with Clinical Laboratory Tests - Mayo Clinic

    Patients with renal impairment: eGFR reported in the EMR within the last 60 days 15-59 mL/min/1.73 m2 with diagnosis of chronic kidney disease. Exclusion ...

  3. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

    Participation eligibility · ALT or AST > 5 times the upper limit of normal. · Subjects with a low glomerular filtration rate (eGFR), specifically: · Pregnancy or ...

  4. Safety And Tolerability Of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) In Real World Scenarios Of Patients With Chronic Kidney Disease (CKD) - Mayo Clinic

    Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m^2. Hemoglobin A1c of ≤9%, if diabetes mellitus present. Ability to give informed consent.

  5. Erlotinib Hydrochloride In Preventing Liver Cancer In Patients With Cirrhosis Of The Liver Undergoing Surgery - Mayo Clinic

    Any prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFR; Participants with a known diagnosis of human ...

  6. Promising developments in the search for glioblastoma therapies - Mayo Clinic

    Activation of STAT3 through combined SRC and EGFR signaling drives resistance to mitotic kinesin inhibitor in glioblastoma. Cell Reports. 2022;39:110991 ...

  7. Publications - Geoffrey Halling, M.D. - Mayo Clinic

    EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. Oncotarget. 2017 Apr 18; 8 (16): ...

  8. A Study to Remodel the Mitral Annulus following Robotic-Assisted Surgical Mitral Valve Repair - Mayo Clinic

    Compromised renal function, defined as eGFR ≤30 (3,4). History of prior moderate or severe contrast reaction including: unresponsiveness, severe ...

  9. A Study Of Concept Elicitation And Cognitive Debriefing Interviews For ADPKD - Mayo Clinic

    Patient has a medically confirmed diagnosis of ADPKD via COD. ADPKD Mayo Class: 1B-1E. eGFR = 30 – 90 ml/min/1.73m2. Patient is willing and capable of ...

  10. Safety, Tolerability And Pharmacokinetics Of AZD1613 In Adults With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Participation eligibility · Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. · eGFR = 45 to 90 mL/min /1.73m2 · Body ...